A double blind placebo randomised controlled trial of Sativex in the management of cannabis withdrawal

Sativex 治疗大麻戒断的双盲安慰剂随机对照试验

• 批准号: nhmrc : 1006036
• 负责人: A/Pr David Allsop
• 金额: $ 16.38万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/double-blind-placebo-cannabis-withdrawal/109141
• 关键词: double; blind; placebo; randomised; controlled

Cannabis is the most commonly used illicit drug in Australia with an estimated 300,000 individuals with cannabis use disorder in Australia. Treatment presentations for cannabis have more than doubled over the last 10 years, yet there is still no medication to help with withdrawal. This proposal will test pure active ingredients in cannabis in a preparation sprayed in the mouth, to wean individuals from cannabis. This will assist them to complete cannabis withdrawal.

大麻是澳大利亚最常用的非法药物，估计有30万人患有大麻使用障碍。在过去10年中，大麻的治疗介绍增加了一倍多，但仍然没有药物帮助戒断。该提案将测试大麻中的纯活性成分，并将其喷在口腔中，以使个人摆脱大麻。这将有助于他们完成大麻戒断。